Antibody inhibiting vplf activity
CA 2426384 A1 · Owner: Shitara, Kenya · Inventors: Shitara, Kenya; Furuya, Akiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An antibody which specifically recognizes a protein containing the amino acid sequence represented by SEQ ID NO:1 and inhibits the activity of this protein as a growth factor. Namely, a monoclonal antibody specifically reacting with human VPLF and inhibiting its activity is constructed. This antibody is usable as a remedy or a diagnostic for diseases in which VPLF participates i.e. diseases associated with abnormal acceleration of angiogenesis eye diseases , based on abnormal angiogenesis arthritis based on abnormal angiogenesis skin , diseases associated with abnormal angiogenesis diseases associated with , abnormal acceleration of vasopermeability diseases associated with abnormal , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 19, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.